lymphoma

Bristol-Myers Squibb Co (NYSE: BMY) announced topline results from two Breyanzi (lisocabtagene maraleucel) studies: TRANSCEND FL Phase 2 trial in relapsed or refractory follicular lymphoma (FL), and TRANSCEND NHL 001 Phase 1 study relapsed or refractory B-cell non-Hodgkin...

Fate Therapeutics Inc (NASDAQ: FATE) showcased interim Phase 1 data from its FT596 program for patients with relapsed / refractory B-cell lymphoma (BCL) at the American Society of Hematology (ASH) Annual Meeting and Exposition.  In the second, third, and fourth dose cohorts of...

Kite Pharma, a Gilead Science Inc company (NASDAQ: GILD), churned out more data for its CAR-T Yescarta in first-line lymphoma patients.  The Company shared the data at the American Society of Hematology (ASH) Annual Meeting & Exposition. In updated results from the...

Viracta Therapeutics Inc (NASDAQ: VIRX) announced final data from its Phase 1b/2 trial of Nana-val in relapsed/refractory (R/R) EBV+ lymphoma. The data were presented at the 2021 American Society of Hematology (ASH) Annual Meeting. Nana-val was well tolerated and demonstrated...

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) revealed initial positive results from a Phase 2/3 trial of intramuscular (IM) administration of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). In Cohort 1c...

Roche Holdings AG's (OTC: RHHBY) mosunetuzumab, a bispecific targeting the CD20 protein on the surface of tumors and the CD3 protein on T cells, posted a 60% complete response rate. The data comes from nearly 100 patients with third-line-or-later follicular lymphoma in Phase 1/2...

Kite Pharma, a Gilead Science Inc's Company (NASDAQ: GILD), announced primary analysis results from the ZUMA-7 Phase 3 trial of Yescarta (axicabtagene ciloleucel) as a one-time infusion. The head-to-head study evaluated Yescarta against standard of care (SOC) for...

Bristol Myers Squibb & Co (NYSE: BMY) released the first disclosure of results from a prespecified interim analysis of Phase 3 TRANSFORM study of Breyanzi (lisocabtagene maraleucel; liso-cel). Breyanzi cut the risk of disease progression, death, and other events by 65% over...

TG Therapeutics Inc (NASDAQ: TGTX) shares are falling after FDA notified the Company that it plans to host an Oncologic Drugs Advisory Committee (ODAC) meeting for marketing application regarding ublituximab/ Ukoniq (umbralisib) (U2 combo). U2 Combo application seeks approval for chronic...

Affimed NV (NASDAQ: AFMD) has announced interim clinical results from the investigator-initiated Phase 1/2 study evaluating cbNK cells pre-complexed with Affimed's innate cell engager (ICE) AFM13. Eighteen patients with CD30-positive relapsed or refractory Hodgkin and non-...

In an SEC filing, Soligenix Inc (NASDAQ: SNGX) disclosed that it cannot file its HyBryte marketing application in the U.S. in 1H of 2022. Citing COVID-19 related disruptions resulting in delays by the commercial active pharmaceutical ingredient manufacturer, the Company cannot...

Kite Pharma, a Gilead Science Inc Company (NASDAQ: GILD), has submitted a supplemental marketing application to the FDA for Yescarta (axicabtagene ciloleucel). The application seeks to expand Yescarta's current indication to include adults with relapsed or refractory large...

The FDA has granted accelerated approval to BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen. The accelerated approval is based on the overall response...

The FDA has granted orphan drug designation to the active ingredient hypericin to treat T-cell lymphoma, extending the target population beyond cutaneous T-cell lymphoma (CTCL) as previously granted. "The FDA's decision to grant and expand our hypericin orphan drug designation...

ADC Therapeutics SA (NYSE: ADCT) has entered into a royalty purchase agreement with HealthCare Royalty Partners for up to $325 million. ADC Therapeutics will receive $225 million upon closing, with an additional $100 million in potential near-term milestone payments...